Last updated on March 2020

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001


Brief description of study

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

Detailed Study Description

Provides up to six months treatment with CuATSM for subjects who have successffulyl completed study CMD-2019-001. [This allows subjects randomized to placebo on study CMD-2019-001 to receive up to six months treatment with CuATSM and provides an up to an additional six months treatment with CuATSM for subjects randomized to CuATSM on study CMD-2019-001]

Clinical Study Identifier: NCT04313166

Find a site near you

Start Over

Macquarie University

Macquarie Park, Australia
0.81miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.